title: Prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy in radioiodine therapy in a cohort of Chinese Graves' disease patients: a pilot clinical study.
abstract: OBJECTIVE
  This study is to assess the prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy for predicting the outcomes of fixed low dose of radioiodine therapy (RIT) in a cohort of Chinese Graves' disease (GD) patients.
  
  
  METHODS
  This is a retrospective study of GD patients who received RIT with a single dose of radioiodine (5 mCi). All the patients received (99m)Tc-pertechnetate thyroid scintigraphy prior to RIT. Thyroid mass, (99m)Tc-pertechnetate uptake, gender, age at diagnosis, duration of the disease, ophthalmopathy, and serum levels of FT4, FT3, TT4, and TT3 prior to RIT were analyzed as potential interference factors for outcomes of RIT.
  
  
  RESULTS
  One hundred and eighteen GD patients who completed RIT were followed up for 12 months. The outcomes (euthyroidism, hypothyroidism, and hyperthyroidism) were found to be significantly associated with thyroid mass and (99m)Tc-pertechnetate uptake. Patients with thyroid mass ≤ 40.1 g or (99m)Tc-pertechnetate uptake ≤ 15.2% had higher treatment success.
  
  
  CONCLUSIONS
  A fixed low dose of 5 mCi radioiodine seems to be practical and effective for the treatment of Chinese GD patients with thyroid mass ≤ 40.1 g and (99m)Tc-pertechnetate uptake ≤ 15.2%. This study demonstrates (99m)Tc-pertechnetate thyroid scintigraphy is an important prognostic factor for predicting the outcomes of RIT.
authors: Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang 310009, China ; Zhejiang University Medical PET Center, Hangzhou, Zhejiang 310009, China ; Institutes of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, Zhejiang 310009, China ; Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, Zhejiang 310009, China.
authors: Haifeng
authors: H
authors: Hou
authors: Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
authors: Shu
authors: S
authors: Hu
authors: Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
authors: Rong
authors: R
authors: Fan
authors: Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
authors: Wen
authors: W
authors: Sun
authors: Department of Clinical Epidemiology and Biostatistics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
authors: Xiaofei
authors: X
authors: Zhang
authors: Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang 310009, China ; Zhejiang University Medical PET Center, Hangzhou, Zhejiang 310009, China ; Institutes of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, Zhejiang 310009, China ; Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, Zhejiang 310009, China.
authors: Mei
authors: M
authors: Tian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D011877:Radionuclide Imaging; D013670:Sodium Pertechnetate Tc 99m / Q000627:therapeutic use; D013961:Thyroid Gland / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D013670:Sodium Pertechnetate Tc 99m